AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca is currently conducting a study titled ‘AQUALIS: Quality of Life of Patients With Chronic Lymphocytic Leukemia Treated With Acalabrutinib in France: a Retrospective Observational Study Based on Data Extracted From the PLATON Database.’ The primary goal is to assess the quality of life (QoL) of patients with Chronic Lymphocytic Leukemia (CLL) treated with acalabrutinib over a 12-month period in a real-world setting. This study is significant as it aims to fill the gap in understanding the real-world QoL of CLL patients, especially those treated with acalabrutinib, a treatment known for its efficacy and favorable safety profile.
The intervention being tested is acalabrutinib, a selective and irreversible small molecule inhibitor of BTK, used as a first or second-line treatment for CLL. Its purpose is to improve the management of CLL, particularly in older patients or those with comorbidities who may not tolerate traditional chemo-immunotherapies well.
The study is designed as a retrospective, observational cohort study using data from the PLATON database. It does not involve any new interventions or additional visits for patients, focusing instead on analyzing existing data to evaluate QoL outcomes.
The study started on April 28, 2025, with the last update submitted on July 17, 2025. These dates are crucial as they mark the timeline for data collection and analysis, with the study currently in the recruiting phase.
The update on this study could have potential market implications for AstraZeneca’s stock performance. Positive results demonstrating improved QoL for CLL patients could enhance investor sentiment and strengthen AstraZeneca’s position in the oncology market, particularly in the competitive landscape of CLL treatments.
The AQUALIS study is ongoing, with further details available on the ClinicalTrials portal.